Shares Held by Insiders

Fully Diluted Shares Held by Insiders

Date

Name

Buy/Sell

$ Value

# Shares

Avg. Price

Title

PRESIDENT AND CEO

VP OF FINANCE AND ACCOUNTING

CHIEF FINANCIAL OFFICER

CHIEF MEDICAL OFFICER

SVP AND GENERAL COUNSEL

President and CEO

VP of Finance and Accounting

Chief Business Officer and CFO

Chief Executive Officer

Principal Accounting Officer

Principal Executive Officer

Chief Medical Officer

Chimerix, Inc., a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 2 clinical trial for treating tumors, which harbor the H3 K27M mutation in glioma patients; ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist that demonstrated enhanced non-competitive DRD2 antagonism relative to ONC201, which is in Phase I clinical trials to treat solid tumors; ONC212, an imipridone agonist of the orphan G protein-coupled receptors (GPCR) tumor suppressor GPR132, as well as ClpP for solid tumors and hematological malignancies, including pancreatic cancer and leukemias; and CMX521, a nucleoside analog antiviral drug candidate for the treatment of SARS-CoV-2 (COVID-19) infection. The company has license agreement with SymBio Pharmaceuticals to develop and commercialize TEMBEXA for human diseases other than orthopoxviruses, including smallpox. Chimerix, Inc. was incorporated in 2000 and is headquartered in Durham, North Carolina.

Chimerix, Inc., a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases.

Datesorted ascending	Name	Buy/Sell	$ Value	# Shares	Avg. Price	Title
2024-02-14	Premium	sold	Premium	Premium	Premium	PRESIDENT AND CEO
2024-02-14	Premium	sold	Premium	Premium	Premium	VP OF FINANCE AND ACCOUNTING
2024-02-14	Premium	sold	Premium	Premium	Premium	CHIEF FINANCIAL OFFICER
2024-02-01	Premium	acquired	Premium	Premium	Premium	PRESIDENT AND CEO
2024-02-01	Premium	acquired	Premium	Premium	Premium	VP OF FINANCE AND ACCOUNTING
2024-02-01	Premium	acquired	Premium	Premium	Premium	CHIEF MEDICAL OFFICER
2024-02-01	Premium	acquired	Premium	Premium	Premium	CHIEF FINANCIAL OFFICER
2024-02-01	Premium	acquired	Premium	Premium	Premium	SVP AND GENERAL COUNSEL
2023-12-29	Premium	gifted	Premium	Premium	Premium	President and CEO
2023-11-17	Premium	bought	Premium	Premium	Premium	-
2023-11-10	Premium	bought	Premium	Premium	Premium	-
2023-09-28	Premium	sold	Premium	Premium	Premium	VP of Finance and Accounting
2023-09-25	Premium	bought	Premium	Premium	Premium	-
2023-08-01	Premium	acquired	Premium	Premium	Premium	President and CEO
2023-05-18	Premium	bought	Premium	Premium	Premium	Chief Business Officer and CFO
2023-05-12	Premium	bought	Premium	Premium	Premium	Chief Executive Officer
2023-05-10	Premium	bought	Premium	Premium	Premium	-
2023-05-08	Premium	bought	Premium	Premium	Premium	-
2023-03-28	Premium	bought	Premium	Premium	Premium	-
2023-01-26	Premium	sold	Premium	Premium	Premium	Principal Accounting Officer
2023-01-17	Premium	acquired	Premium	Premium	Premium	Principal Executive Officer
2023-01-17	Premium	acquired	Premium	Premium	Premium	Principal Accounting Officer
2023-01-17	Premium	acquired	Premium	Premium	Premium	Chief Medical Officer
2023-01-17	Premium	acquired	Premium	Premium	Premium	Chief Business Officer and CFO
2023-01-17	Premium	acquired	Premium	Premium	Premium	Chief Executive Officer

CMRX - Chimerix Inc Stock Price, Fair Value and News

Latest Insider Trading transactions for CMRX